Clinical Trial Update: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing ivosidenib plus azacitidine with or without venetoclax in adults with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for inten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Tibsovo (ivosidenib)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: RECRUITING